COMPANY
Memgen
Memgen is applying its expertise in immune-regulatory systems to develop a range of immunotherapies, including viral immunotherapies, cell-based immunotherapies (TILs), and infectious disease vaccine adjuvants. From company website Source · Oct 13, 2026
Timeline
- Trial start Phase 1: MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors source ↗
- Trial start I: A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL source ↗
- Trial start I: A Phase I Extension Trial of Repeated Infusions of ISF35 source ↗
- Trial start I: A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) source ↗
Upcoming milestones
- 2027-02 (ESTIMATED) · Phase 1 · MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors · NCT05076760
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Phase 1 | Recruiting | Apr 21, 2022 | 2027-02 (estimated) |
| NCT00772486 | A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | I | Completed | 2008-09 | 2011-04 (actual) |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | I | Completed | 2007-05 | 2008-09 (actual) |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | I | Completed | 2006-06 | 2008-03 (actual) |